|

Axl/Mer/CSF1R Inhibitor Q702 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702, Q 702, Q-702, Q702, RTK Inhibitor Q702

Pipeline

Phase 1: 1

Top Sponsors

  • Mayo Clinic1

Indications

  • Refractory Rosai-Dorfman-Destombes Disease1
  • Refractory Interdigitating Dendritic Cell Sarcoma1
  • Refractory Histiocytic Sarcoma1
  • Refractory Fibroblastic Reticular Cell Sarcoma1
  • Recurrent Rosai-Dorfman-Destombes Disease1

Scottsdale, Arizona1 trial

Q702 for the Treatment of Patients With Hematologic Malignancies

Mayo Clinic in Arizona

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.